Bamlanivimab: Continued monitoring
As for all medicines, Health Canada will continue to monitor the safety of bamlanivimab in Canada closely. We will take prompt action should any safety concerns arise.
Health Canada will provide updates on post-market activities related to bamlanivimab in the Post-Authorization Activity Table (PAAT) found in the vaccines and treatments regulatory portal.
Report a problem or mistake on this page
- Date modified: